跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
SYNAGIS - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
SYNAGIS
Authorized
STANDARD
SYNAGIS
astrazeneca canada inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
1a2cf140d82ddf68
Company
astrazeneca canada inc
Type
Standard
Approval Details
Approval Id
1a2cf140d82ddf68
Drug Approval Canada Name
SYNAGIS
Product Name
SYNAGIS
Status
Marketed
Status Date
2022-03-24
Original Market Date
2016-11-03
Din
02438372
Drug Class
Human
Dosage Form
Solution
Route Of Administration
Intramuscular
Schedule
Schedule D , Prescription
Ahfs
08:18.24
Atc Original
J06BD01 PALIVIZUMAB
Atc Name
j 06 bd 01
Aig Number
0147401002
Company Name
astrazeneca canada inc
Company Address
1004 Middlegate Road, Suite 5000, Mississauga, Ontario, Canada, L4Y 1M4
Active Ingredients
PALIVIZUMAB
50 MG / 0.5 ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
1a2cf140d82ddf68
Type
Standard
Back to Health Canada Approvals